MASH / NASH: key endpoint results by drug

The key endpoints of MASH / NASH trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the MASH / NASH page.

MASH resolution without fibrosis worsening

MASH resolution without fibrosis worsening in MASH / NASH: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
pemvidutide52.1%a19.1%+33pemvidutide 1.8mg · wk 24NCT05989711 Phase 2, primary
Resmetirom27.4%14.7%+12.7wk 36 · n 73NCT02912260 Phase 2, secondary

Drugs checked with no result here: 33 not reported, 2 not posted, 5 trial running.

Fibrosis stage, change

Fibrosis stage, change in MASH / NASH: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Omega-3-acid ethyl esters (Lovaza)0.30.2+0.1wk 78 · n 46NCT00760513 Phase 4, primary
Tesamorelin00±0wk 52 · n 18NCT03375788 Phase 2, secondary

Drugs checked with no result here: 31 not reported, 3 not posted, 6 trial running.

Liver fat (MRI-PDFF), change

Liver fat (MRI-PDFF), change in MASH / NASH: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Ezetimibe11.6%16.4%−4.8wk 24 · n 23NCT01766713 Phase 2, primary
Omega-3-acid ethyl esters (Lovaza)-7.9%-4.6%−3.3wk 78 · n 46NCT00760513 Phase 4, primary
Resmetirom-8.2%-2.9%−5.3wk 36 · n 74NCT02912260 Phase 2, secondary
survodutide-13.0%-1.9%−11.16.0 mg · wk 48 · n 51NCT04771273 Phase 2, secondary

Drugs checked with no result here: 31 not reported, 6 trial running, 1 not posted.

ALT, change

ALT, change in MASH / NASH: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Resmetirom-15.411−26.4wk 36 · n 78NCT02912260 Phase 2, secondary
Sitagliptin3428.5+5.5wk 24 · n 25NCT01963845 Phase 2, secondary

Drugs checked with no result here: 32 not reported, 2 not posted, 6 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in MASH / NASH were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.